Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sorafenib plus infusional 5-fluorouracil in advanced hepatocellular carcinoma
2007-000747-10Phase 2Completed
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib and fluorouracil in hepatocellular carcinoma (HCC), sponsored by Azienda Ospedaliero-Universitaria Pisana. Primary endpoint: Non-progressive disease after 6 cycles. Started Mar 2007; status: completed.
02
Drugs
sorafenibfluorouracil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2007-000747-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000747-10.